Overview

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Status:
RECRUITING

Trial end date:
2031-08-08

Target enrollment:

Participant gender:

Summary

The researchers are doing this study to see if alectinib in combination with duvelisib is a safe and effective time-limited treatment for people with relapsed or refractory ALK+ anaplastic large cell lymphoma (ALCL). The researchers will test different doses of the study drugs to find the highest doses that cause few or mild side effects in participants. Once they find this dose combination, they will test it in a new group of participants to learn how long the effect of the combination lasts after the end of treatment

Phase:

PHASE1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

Genentech, Inc.
Secura Bio, Inc.

Treatments:

alectinib
duvelisib